GEM103 for Geographic Atrophy (GA) - Dry AMD affects approximately 16 million patients in the US, with about 90% (15 million) having dry AMD[6] - 80% (12 million) of dry AMD patients have variants in the CFH gene[6,9] - Gemini's GEM103 targets patients with genetically reduced Factor H function, aiming for precision medicine in AMD[4] - Phase 2a ReGAtta study enrolled patients with GA secondary to AMD, enriched for CFH genetic risk variants, with 85% having HH/HY variants[15] - Phase 2a data supports advancing a 500μg dose of GEM103 to late-stage development[16,20,29] GEM103 Safety and Biological Activity - GEM103 was generally well-tolerated in the ReGAtta study, with no increased risk for CNV in the GA population after over 500 injections[16,17] - 27.4% of patients experienced ocular AEs in the study eye, with one case of iritis related to GEM103, but no AEs led to discontinuation[17] - GEM103 demonstrated biological activity by reducing elevated complement biomarkers in GA patients, including a 43% reduction in Ba and a 37% reduction in C3a[16,22] Gemini's Pipeline and Financials - Gemini is also developing GEM307, a CFH potentiating antibody, with IND submission targeted for 1H 2022[7,33] - Gemini has a Phase 2a study of GEM103 as an adjunct to SOC in patients with neovascular AMD (nAMD)[30] - Gemini is capitalized to support milestones in 2021 and has a cash runway into 2023[32,33]

WASHINGTON, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39438 GEMINI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Cha ...

© Gemini Therapeutics, 2021 © Gemini Therapeutics, 2021 August 2021 Disclaimer 2 Forward-Looking Statements Certain statements in this press release and the information incorporated herein by reference may constitute "forward-looking statements" for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Exact Name of Registrant as Specified in its Charter) Delaware 85-1612845 ( State or other jurisdiction of incorporation or organization) 300 One Kendall Square, 3rd Floor Cambridge, MA 02139 (Address of principal executive offices) (Zip Code) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTIO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39438 GEMINI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39438 GEMINI THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) | Delaware 85-1612845 | | | | --- | --- | --- ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) | Delaware | 85-1612845 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification Number) | 600 Montgomery Street, Suite 4500 San Francisco, CA 94111 (Mark One) ☒ Quarterly Report PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSI ...